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hypertensive ADPKD patients early in the
disease course
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Abstract
Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney
disease and is characterized by gradual cyst growth and expansion, increase in kidney volume with an ultimate
decline in kidney function leading to end stage renal disease (ESRD). Given the decades long period of stable
kidney function while cyst growth occurs, it is important to identify those patients who will progress to ESRD.
Recent data from our and other laboratories have demonstrated that metabolic reprogramming may play a key role
in cystic epithelial proliferation resulting in cyst growth in ADPKD. Height corrected total kidney volume (ht-TKV)
accurately reflects cyst burden and predicts future loss of kidney function. We hypothesize that specific plasma
metabolites will correlate with eGFR and ht-TKV early in ADPKD, both predictors of disease progression, potentially
indicative of early physiologic derangements of renal disease severity.
Methods: To investigate the predictive role of plasma metabolites on eGFR and/or ht-TKV, we used a non-targeted
GC-TOF/MS-based metabolomics approach on hypertensive ADPKD patients in the early course of their disease.
Patient data was obtained from the HALT-A randomized clinical trial at baseline including estimated glomerular
filtration rate (eGFR) and measured ht-TKV. To identify individual metabolites whose intensities are significantly
correlated with eGFR and ht-TKV, association analyses were performed using linear regression with each metabolite
signal level as the primary predictor variable and baseline eGFR and ht-TKV as the continuous outcomes of interest,
while adjusting for covariates. Significance was determined by Storey’s false discovery rate (FDR) q-values to correct
for multiple testing.
Results: Twelve metabolites significantly correlated with eGFR and two triglycerides significantly correlated with
baseline ht-TKV at FDR q-value < 0.05. Specific significant metabolites, including pseudo-uridine, indole-3-lactate,
uric acid, isothreonic acid, and creatinine, have been previously shown to accumulate in plasma and/or urine in
both diabetic and cystic renal diseases with advanced renal insufficiency.
Conclusions: This study identifies metabolic derangements in early ADPKD which may be prognostic for ADPKD
disease progression.
Clinical trial: HALT Progression of Polycystic Kidney Disease (HALT PKD) Study A; Clinical www.clinicaltrials.gov
identifier: NCT00283686; first posted January 30, 2006, last update posted March 19, 2015.
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Background
Autosomal dominant polycystic kidney disease (ADPKD)
is the most common hereditary kidney disorder and af-
fects 1/1000 individuals. It is characterized by gradual en-
largement of numerous cysts in the kidneys over decades,
and the disease process begins long before loss of esti-
mated glomerular filtration rate (eGFR) occurs. There are
at least three definite genetic causes of ADPKD. The ma-
jority of ADPKD cases (~ 75%) are caused by mutations in
polycystin 1 [1], and second most common (~ 15%) are
mutations in polycystin 2 (PKD2) [2]. Recently a third
causative gene in ADPKD and autosomal dominant poly-
cystic liver disease (ADPLD) was identified to be GANAB,
responsible for 0.3% of all ADPKD [3]. Mutations in
GANAB result in a defect in the maturation of PKD1 such
that it fails to localize in the plasma membrane [3]. PKD1
binds to PKD2 [4] and this protein complex signals tubu-
lar morphogenesis through the formation of an
ion-channel [5]. When GANAB is mutated and PKD1
maturation is mostly blocked, then PKD1 doesn’t interact
correctly with PKD2 and PKD2 fails to localize in the cilia
[3]. This leaves 5–10% of ADPKD patients with no detect-
able mutation after DNA sequencing of their PKD1 and
PKD2 genes [6].
The course of ADPKD is variable depending not only
on which gene is mutated [7] and the strength of the
mutation [8], but also on environmental factors such as
dietary sodium intake [7] and smoking exposure [9], both
of which contribute to disease severity and progression. A
high sodium intake could contribute to an increased rate
of disease progression in ADPKD via various possible
mechanisms [10] and not just by its effects on hyperten-
sion. Smoking has been found to be associated with estab-
lished proteinuria and this is highly associated with
hypertension and a more severe renal cystic phenotype
[9]. Hypertension is common and occurs early in ADPKD,
prior to loss of kidney function, and is associated with
more rapid disease progression and increased kidney size
[11, 12]. With the recognition that ADPKD is at least in
part a metabolic disease as has become evident with the
discovery that glucose, histidine, glutamine, and arginine
metabolic pathways are reprogrammed [13–16], there is
the opportunity to investigate such pathways to develop
new therapies for this disease.
With the continuing advent of new therapeutic ap-
proaches, identifying patients at risk for progression to
ESRD has become paramount. The Consortium for Radio-
logic Imaging Studies of Polycystic Kidney Disease
(CRISP) study established ht-TKV as assessed by magnetic
resonance imaging as an accurate and reliable measure of
renal cyst burden, which also strongly predicts those pa-
tients who will progress to advanced chronic kidney dis-
ease (CKD) [17]. Ht-TKV is now approved by the FDA as
both a prognostic and a clinical trial enrichment imaging
biomarker for ADPKD [18]. We asked whether plasma
metabolomic analyses can further identify circulatory sig-
natures which are indicative of increased ht-TKV or kid-
ney function (eGFR) in individuals at risk for progression
to ESRD early in the course of disease. Such studies will
shed light on mechanisms of disease, including metabolic
reprogramming. The HALT A clinical trial was designed
and developed to test the hypothesis that rigorous blood
pressure control (< 110/75mmHg) or combined angioten-
sin converting enzyme inhibitor and angiotensin receptor
blocking therapy would slow disease progression defined
as the rate of increase in ht-TKV and the chronic slope of
decline in eGFR. Importantly, low blood pressure control
was found to have a significant protective impact on both
the rate of ht-TKV increase as well as the chronic eGFR
slope. For this study, we now have utilized plasma from
the baseline visit from participants in the HALT-A ran-
domized clinical trial [12, 19], after stopping all antihyper-
tensive medications for at least two weeks, in an attempt
to correlate expression of specific metabolites with simul-
taneously measured eGFR and ht-TKV.
Methods
Ethics approval and consent to participate
IRBs at each participating center approved the HALT-A
clinical trial. These included University of Colorado
Health Sciences Center, Denver (Aurora), Colorado;
Emory University School of Medicine, Atlanta, Georgia;
University of Kansas Medical Center, Kansas City, Kansas;
Tufts Medical Center, Boston, Massachusetts; Beth Israel
Deaconess, Boston, Massachusetts; Cleveland Clinic,
Cleveland, Ohio; Mayo Clinic, Rochester, Minnesota. All
subjects provided written consent, and parental consent
was required and obtained for all participating subjects
between the ages of 15 and 18 years of age at each partici-
pating site. Two Data Coordinating Centers were involved
in the HALT-A clinical trial: Washington University, St.
Louis Missouri and the University of Pittsburgh,
Pittsburgh, Pennsylvania. IRB study approval was obtained
at each Data Coordinating Center.
Subject enrollment
This study was approved by the Institutional Review
Boards both at the University of California, Davis, and at
the University of Chicago. The HALT Progression of
Polycystic Kidney Disease (HALT PKD, NCT00283686,
http:// clinicaltrials.gov) Study A is a double-blind,
placebo-controlled trial consisting of 588 hypertensive
participants (15 to 49 years of age, with eGFR > 60ml/
1.73 m2) [12]. Briefly, subjects provided written consent
and were enrolled, after which antihypertensive medica-
tions were withdrawn for two weeks. Patients who dem-
onstrated elevations in blood pressure during washout
were placed on labetolol therapy. At baseline, blood was
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obtained for centralized eGFR measures, MR imaging
performed for ht-TKV measurement and plasma and
urine collected and appropriately stored for future ana-
lyses. Plasma samples were handled immediately at each
participating clinical center and stored within 30 min at
− 80 degrees. Samples were shipped in bulk to the
NIDDK repository for storage prior to this study. Sub-
jects were randomized in a 2 × 2 factorial design to de-
termine whether rigorous blood pressure control (< 110/
75mm HG vs. < 130/80 mmHg) or additive inhibition of
the renin-angiotensin-aldosterone-system (RAAS) im-
pacted disease progression. The primary outcomes of
our study were baseline ht-TKV and eGFR measures.
We analyzed baseline fasting plasma samples obtained
from a subset of 277 Caucasian ADPKD patients who
were known to have mutations in either the PKD1 and
PKD2 genes.
Non-targeted metabolomics analysis
Samples and standards were analyzed as described [20].
Peaks were deconvoluted and detected using Leco Chro-
maTOF software and were matched to FiehnLib mass
spectra and retention time libraries. The Binbase software
was used for post-curation and peak replacements, and
the sum of intensities for all known compounds was used
to normalize data.
Non-targeted lipidomics analysis
Samples and standards were analyzed as described [21].
The sample temperature was maintained at 4 °C.
Statistical analysis
Metabolomic and lipidomic analyses were performed on
all 277 plasma samples by gas chromatography-time of
flight mass spectrometry (GC-TOF/MS). Patient samples
were analyzed along with 35 (metabolomics) and 36
(lipidomics) splits of the “reference” (pooled) quality
control sample placed evenly in between patient samples
for quality control assessment. Run order of patient
samples was randomly determined. Note that for the
lipidomics data, one patient sample showed anomalous
behavior and was markedly dispersed from the rest of
the patient samples (i.e., contained values above and
below 3 standard deviations from the mean) and thus re-
moved from further analysis.
A total of 116 plasma metabolites and 101 lipids were
identified, quantitated, and included in downstream stat-
istical analysis. Also 174 unknown plasma metabolites
were analyzed separately in the same manner described
below. For lipidomic data, lipids quantified in fewer than
50% of samples were discarded from downstream ana-
lysis to reduce the bias that could be induced by imput-
ation due to the detection limit. Unobserved values for
any remaining undetected lipid below the pre-defined
detection limit were imputed as one-half of the
lipid-specific minimum of the observed values prior to
normalization and statistical inference tests.
For between-sample normalization, the intensity values
for each sample were summed, and the median value of the
sums across all samples were determined. The intensity
values of each sample were then scaled such that the sum
of the scaled intensities equaled the median value of all
samples. Thus, the sum of the scaled intensities was the
same for all samples. Normalized intensity values were then
log2 transformed to reduce the influence of extreme values
and to meet the homogeneity of variance assumption.
Prior to assessing the association between metabolite in-
tensity levels and disease severity (baseline eGFR and
ht-TKV), we assessed the distributions of eGFR and
ht-TKV and then log transformed them to meet normality
and homoscedasticity of linear regression models. To
identify individual metabolites whose intensities are sig-
nificantly associated with eGFR and ht-TKV, we per-
formed association analyses using linear regression with
each metabolite signal level as the primary predictor vari-
able and baseline eGFR and ht-TKV as the two outcomes
of interest, analyzed separately. All analyses accounted for
the covariates attributed to the HALT-A study design in-
cluding age, sex, PKD genotype (PKD1 or PKD2), and par-
ticipating clinical site of sample collection. Other HALT
covariates, including baseline systolic and diastolic blood
pressure, weight, body mass index (BMI), height-adjusted
liver volume, and urine levels for sodium, potassium, and
creatinine, were evaluated for inclusion in multiple linear
regression models to determine whether any of those co-
variates are influential in estimating the magnitude of as-
sociation of metabolite levels with the outcomes. Variable
inclusion and exclusion were determined based on Akaike
weight-based relative importance (RI) scores [22], with a
suggestive threshold of 0.80 in conjunction with likelihood
ratio tests (LRT) at p-value < 0.05. Multicollinearity was
inspected for possible collinearity issues using variance in-
flation factor (VIF) score with a suggestive threshold of
2.5. We investigated potential effect modifiers such as sex
and PKD genotype by adding interaction terms in regres-
sion models. When an interaction term reached statistical
significance, post-hoc analysis was performed stratified by
the effect modifier. Five missing values for BMI were im-
puted with the mean of the observed values. We used the
Storey’s false discovery rate (FDR) q-values to correct for
multiple testing [23]. All statistical analyses were con-
ducted in R (version 3.4.) language and environment.
Results
Reproducibility of metabolomics and lipidomics data
Due to the large number of samples (277; Table 1) and
the necessity to process the samples over a prolonged
time period of several days, we first investigated
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reproducibility and time-dependent variation using the
repeated measurements from the 35 and 36 technical
replicates, for metabolomics and lipidomics respectively
of the reference quality control sample which were
inserted throughout the GC-TOF/MS analysis to assess
for systematic shifts among samples. Boxplots of the in-
tensity values of the reference sample replicates revealed
no systematic time-dependent pattern in the magnitude
or distribution of intensities (Additional file 1: Figure S1
and S2). In order to provide a direct quantitative meas-
ure of technical between-sample variability, we calcu-
lated the coefficient of variation (CV) across the 35 and
36 measurements for each metabolite and lipid in the
reference sample. The CV values of the 35–36 replicates
ranged from 0.006 to 0.445 with mean = 0.051 and SD =
0.045 for metabolites and from 0.232 to 0.250 with
mean = 0.241 and SD =0.004 for lipids. These low CV
values demonstrate adequate technical reproducibility of
sample analyses during the course of the GC-TOF/MS
experiment.
Selection of accountable covariates in association with
metabolite signals of baseline eGFR and ht-TKV
To determine which covariates should be included in
multiple regression models, Akaike weight-based RI
scores were calculated as a merit for importance of in-
clusion of each covariate in a model for all metabolites
(ranged from 0.29 to 0.905 for eGFR and from 0.28–
0.812 for ht-TKV) and final variable selection was car-
ried out via likelihood ratio test (LRT). Age, genotype,
sex, site of sample collection, and BMI were significantly
(p < 0.05) influential in association between metabolites
and outcomes, eGFR and ht-TKV (Fig. 1) and thus we
retained these covariates in the final models. Although
the site of sample collection was not significant for
ht-TKV at p-value < 0.05, we decided to include it in the
final model to account for possible study site differences.
The variable selection procedures led to the following
final models for association analysis explicitly:
1) eGFR = α + β1*M_Signal + β2*Age + β3*Genotype
+ β4*Sex + β5*Site + β6*BMI.
2) ht-TKV = α + β1*M_Signal+ β2*Age + β3*Genotype
+ β4*Sex + β5*Site + β6*BMI.
where M_ Signal is the signal level of a given metabolite/
lipid.
We further investigated potential multicollinearity
issues among the selected variables in the above models
and found no presence of collinearity.
Identification of plasma metabolites and lipids associated
with baseline eGFR and ht-TKV
After accounting for the covariates discussed above, we dis-
covered that 20 metabolites significantly associated with
eGFR at p < 0.05. Of those, 12 metabolites remained signifi-
cant at FDR q-value < 0.05 (Table 2). All of the significant
metabolites exhibited negative associations with eGFR,
meaning that the metabolite levels were increased with
decreasing eGFR levels (Fig. 2). Of note, indole-3-lactate is
an exogenously produced microbial metabolite, while
pseudo-uridine is a known uremic toxin (see Discussion).
We next evaluated metabolites that associated with
ht-TKV. Ten metabolites were found to be significantly
associated with ht-TKV at p < 0.05; however, none of them
maintained their significance at FDR q-value < 0.05
(Table 3). Four metabolites (taurine, tyrosine, glutamic
acid, and 2-hydoxybutanoic acid) were negatively corre-
lated with ht-TKV, while the others exhibited a positive
correlation (Fig. 2).
In analyzing the lipidome, we discovered 11 lipids which
were significantly associated with eGFR at p < 0.05. How-
ever, no lipids remained significant at FDR q-value < 0.05.
Acylcarnitines and triglycerides exhibited negative associa-
tions with eGFR, and phosphatidylcholines and diglyceride
exhibited positive associations (Table 4). Upon analysis of
the relationship between the lipidome and ht-TKV, we
found that five triglycerides and one sphingomyelin were
significantly associated with ht-TKV at p < 0.05, however,
of these only two triglycerides maintained their signifi-
cance at FDR q-value < 0.05 (Table 5). All six of these
lipids exhibited positive associations with ht-TKV.
Table 1 Summary statistics of patient characteristics with
metabolomics data
Variable Caucasian Patients
(n = 277)
Mean (SD) N of Missing
Age (years) 36.87 (8.11) 0
Sex 0
Female, no (%) 132 (47.7%)
Male, no (%) 145 (52.3%)
PKD Genotype 0
PKD1, no (%) 226 (81.6%)
PKD2, no (%) 51 (18.4%)
Body Mass Index (BMI) 27.03 (5.05) 5
Height-Adjusted Liver Volume, mL 1147.93 (525.12) 9
Diastolic Blood Pressure, mmHg 80.02 (10.37) 2
Systolic Blood Pressure, mmHg 126.23 (12.85) 2
Urine Creatinine Level (mEq/day) 1478.97 (742.86) 3
Urine Potassium Level (mEq/day) 56.41 (28.17) 7
Urine Sodium Level (mEq/day) 174.82 (85.20) 3
Height-Adjusted Total Kidney Volume
(ht-TKV, mL)
721.62 (420.75) 4
Estimated glomerular filtration rate
(eGFR, ml/min)
90.55 (18.19) 0
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Assessment of effect modification by sex or PKD
genotype
We further investigated whether the relationship between
metabolite level and eGFR or ht-TKV differ depending on
patient’s sex or their PKD genotype, to evaluate the possi-
bility that either could have a significant role in metabolo-
mics signature expression in association with eGFR or
ht-TKV. To accomplish this, we added an interaction term
to the model depicted by equation 1) above for eGFR and
to the model depicted by equation 2) above for ht-TKV.
For eGFR, none of the metabolites showed significant ef-
fect modification by sex or genotype at FDR q-value< 0.05
(Additional file 2: Table S1). For significant metabolites at
p < 0.05, the direction of the metabolite-eGFR association
was generally reversed by sex. Positive metabolite-eGFR as-
sociations for females were altered to negative associations
for males, and vice-versa; similar data were demonstrated
for metabolite-PKD genotype associations (Fig. 3). By con-
trast, creatinine exhibited negative associations for both
males and females, but at different degrees: the magnitude
of association was 3-fold greater in males compared to fe-
males (Fig. 3 (a), Additional file 2: Table S1).
For ht-TKV, none of the metabolites showed significant ef-
fect modification by sex or genotype at FDR q-value < 0.05
(Additional file 2: Table S2). The majority of the metabolites
that displayed significant effect modification by sex or
genotype at p < 0.05 modified the direction of the
metabolite-ht-TKV association (Fig. 3). Pseudo-uridine and
myo-inositol exhibited positive association regardless of sex,
but their magnitude of association differed depending on
sex. The degree of association for pseudo-uridine was 7-fold
greater in males compared to females, and for myo-inositol
was 15-fold greater in males than females (Fig. 4(a), Add-
itional file 2: Table S2).
For both eGFR and ht-TKV, no lipids showed significant
effect modification by sex or genotype at FDR q-value < 0.05
(Additional file 1: Tables S1 & S2). The majority of those
lipids significant at p-value < 0.05 had the directionality of
their associations with eGFR (Fig. 3) and ht-TKV (Fig. 4) al-
tered by sex and genotype, respectively. It should be noted
that none of the metabolites and lipids reached
FDR-adjusted significance after taking multiple testing into
account and thus further investigation is needed to validate
whether sex or genotype are necessary to treat them as ef-
fect modifiers in the associations with eGFR or ht-TKV for
metabolites or lipids.
Association of metabolites and lipids with eGFR and ht-
TKV are exclusively independent
In the above results, we have identified metabolites and
lipids associated with eGFR and ht-TKV. As eGFR and
ht-TKV are clinically correlated traits for disease severity,
we decided to perform further analysis using those out-
comes as covariates in an attempt to identify metabolites
associated only with eGFR or ht-TKV exclusively independ-
ent of each other. To accomplish this, ht-TKV was added
Fig. 1 Boxplots of likelihood ratio test (LRT) p-values of 290 metabolites determining significance of each of the HALT covariates to include in the
final analysis models for both (a) eGFR and (b) ht-TKV. The dashed line represents the p = 0.05 significance level
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as an additional covariate to the model depicted by equation
1) for eGFR as previously described, while eGFR was added
as an additional covariate to the model depicted by equation
2) for ht-TKV. When controlled for ht-TKV as a covariate,
four metabolites were determined to be significantly associ-
ated with eGFR at FDR q-value < 0.05, including
pseudo-uridine, indole-3-lactate, creatinine, and uric acid
(Additional file 2: Table S3); all of which were among the
twelve metabolites previously identified as significant at FDR
q-value< 0.05 for eGFR without controlling for ht-TKV
(Table 2). Directionality of the eGFR-metabolite association
remained unchanged compared to the ht-TKV unadjusted
analysis results. All significant metabolites exhibited negative
associations with eGFR independent of ht-TKV, with the ex-
ception of pipecolinic acid which demonstrated a positive
relationship with eGFR. No lipids were determined to be
significant at the FDR q-value< 0.05 level (Additional file 2:
Table S3).
When evaluating ht-TKV while controlling for eGFR
as a covariate, only taurine was found to be significant at
p < 0.05, although it was not significant at FDR q-value
< 0.05 (Additional file 2: Table S3). Taurine was also
found to be associated with ht-TKV in the previous
analysis that did not control for eGFR as a covariate
(Table 3). Adjustment for eGFR did not alter the direc-
tionality of association between the metabolite and
ht-TKV. In addition, triglyceride (51:3) was significant at
FDR q-value< 0.05, as previously found without control-
ling for eGFR (Table 5), while the directionality of the as-
sociation remains unchanged regardless of controlling for
eGFR as a covariate in the analysis. The eGFR- and
ht-TKV unique metabolites therefore, suggest that even
those two highly correlated traits may be mediated, at
least in part, by different metabolic pathways in kidney
function.
Discussion
Many metabolic disorders have been associated with
ADPKD [24], including hypocitraturia [25, 26], hypo-
magnesiuria [25, 27, 28], hyperuricemia and gout [29],
hypophosphataemia [30], altered arginine metabolism
[15], abnormal lipid metabolism [31, 32] and nephro-
lithiasis [25, 27]. Recently the Warburg effect metabolic
change that is characteristic of cancer has been identi-
fied in ADPKD [13].C-Glucose tracking in a kidney spe-
cific PKD1-null mouse model found that cystic kidneys
Table 2 Plasma metabolites significantly (p < 0.05) associated with baseline eGFR. Effect size represents the magnitude and direction
(+/−) of association between a given metabolite and eGFR, estimated by linear regression, while controlling for the selected HALT
covariates, age, sex, genotype, site of sample collection, and BMI. KEGG ID is the metabolite identifier for Kyoto Encyclopedia of
Genes and Genomes (KEGG) and PubChem ID is for the chemical molecule database maintained by the National Center for
Biotechnology Information
Metabolite Effect Size (SD) p-value FDR q-value KEGG ID PubChem ID
pseudo uridine −0.1796 (0.023) < 0.0001 < 0.0001 C02067 15,047
indole-3-lactate −0.1204 (0.021) < 0.0001 < 0.0001 C02043 92,904
creatinine −0.0616 (0.016) 0.0002 0.0040 C00791 588
isothreonic acid −0.0616 (0.017) 0.0004 0.0076 C21649 151,152
uric acid −0.0508 (0.016) 0.0016 0.0249 C00366 1175
beta-alanine −0.0369 (0.012) 0.0027 0.0349 C00099 239
isothreitol −0.0504 (0.017) 0.0034 0.0369 C16884 169,019
Arabitol −0.0431 (0.015) 0.0038 0.0369 C01904 94,154
ribonic acid −0.0577 (0.020) 0.0049 0.0410 C01685 5,460,677
indole-3-acetate −0.0450 (0.016) 0.0061 0.0410 C00954 802
citric acid −0.0685 (0.025) 0.0063 0.0410 C00158 311
L-gulonic acid −0.0605 (0.022) 0.0063 0.0410 C00800 6,857,417
salicylic acid −0.0166 (0.006) 0.0092 0.0532 C00805 338
myo-inositol −0.0421 (0.016) 0.0096 0.0532 C00137 892
trans-4-hydroxyproline −0.0428 (0.017) 0.0115 0.0595 C01157 5810
Sucrose −0.0210 (0.009) 0.0237 0.1148 C00089 5988
2,3-dihydroxybutanoic acid NIST −0.0364 (0.017) 0.0294 0.1269 250,402
Glycine −0.0492 (0.022) 0.0295 0.1269 C00037 750
levoglucosan −0.0176 (0.008) 0.0342 0.1396 2,724,705
Lyxitol −0.0244 (0.012) 0.0463 0.1796 C00532 439,255
bold Q-values indicate signficance, <0.05
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had increased aerobic glycolysis, and transcriptomics of
human ADPKD kidneys revealed gluconeogenesis en-
zymes were downregulated while some glycolytic en-
zymes were upregulated [33]. For this report, we asked
which plasma metabolites can serve as indicative of
baseline eGFR and ht-TKV in the HALT A cohort of
hypertensive ADPKD patients with relatively preserved
(> 60ml/min) kidney function. We found several metab-
olites that significantly correlated with eGFR and two
lipids that correlated with ht-TKV at FDR q-value< 0.05.
All of the metabolites which correlated with eGFR had
plasma concentrations inversely correlated with the pa-
tient’s eGFR. Since all of the significant (FDR q < 0.05)
metabolites showed negative associations with eGFR, it
is possible that their increased presence is due merely to
decreased filtration or tubular reabsorption. However, in
light of previous findings of these metabolites in uremic
serum, it is possible that disease specific changes are
Fig. 2 Heatmap of significantly (p < 0.05) associated metabolites with (a) eGFR and (b) ht-TKV. Rows: patients sorted by their outcome values
from high to low; Columns: metabolites. Dendrogram clustering on the X-axis indicates metabolite similarity. Expression values are log2
transformed. Red and green color intensity indicate positive and negative intensity
Table 3 Plasma metabolites significantly (p < 0.05) associated with baseline ht-TKV. Effect size represents the magnitude and
direction (+/−) of association between a given metabolite and ht-TKV, estimated by linear regression, while controlling for the
selected HALT covariates, age, sex, genotype, site of sample collection, and BMI
Metabolite Effect Size (SD) p-value FDR q-value KEGG ID PubChem ID
pseudo uridine 0.2273 (0.082) 0.0061 0.3375 C02067 15,047
aminomalonate 0.1240 (0.047) 0.0094 0.3375 C00872 100,714
Taurine −0.0577 (0.024) 0.0151 0.3375 C00245 1123
Tyrosine −0.1984 (0.082) 0.0156 0.3375 C00082 6057
isothreonic acid 0.1333 (0.055) 0.0166 0.3375 C21649 151,152
glutamic acid −0.1111 (0.048) 0.0217 0.3677 C00025 33,032
indole-3-lactate 0.1544 (0.070) 0.0273 0.3965 C02043 92,904
myo-inositol 0.1080 (0.052) 0.0373 0.4075 C00137 892
2-hydroxybutanoic acid −0.0940 (0.045) 0.0384 0.4075 C05984 440,864
Beta-D-fucose 0.0913 (0.046) 0.0482 0.4075 C02095 439,650
Kim et al. BMC Nephrology           (2019) 20:66 Page 7 of 12
related to the utilization or transport of these metabo-
lites. It is of great interest that these metabolites were
seen to be increased in individuals with relatively pre-
served kidney function (Table 1), which suggests that
there may be an early disruption of their transport or
utilization in patients with kidney disease considered to
be early with normal kidney function.
Non-targeted metabolomics is a powerful tool to gen-
erate hypotheses and discover novel small molecular
biomarkers that may have therapeutic impact. However,
there are limitations to this technique [34], some of
which are apparent in this study. In most GC/MS-based
metabolomics studies, it is common to come across un-
identified metabolites for which a mass/charge ratio is
present but structural identification is lacking. Many of
these compounds can be identified by nuclear magnetic
resonance or other advanced target-specific techniques,
but such analysis requires prior knowledge of specific
targets as well as a substantial investment and consider-
ably larger quantities of starting material [35]. In this
study, one such metabolite, 191801, was found to be
highly correlated with eGFR (FDR q < 0.0001) even after
controlling for ht-TKV as a covariate (Additional file 2:
Table S3). While we can infer properties and the possible
origin of this metabolite based on other studies in the
analyzing laboratory (i.e. that it is likely of microbial ori-
gin), structural information on this metabolite at this
point is lacking.
We are the first to examine the metabolome of plasma
from ADPKD patients with intact kidney function. Other
ADPKD metabolomics studies have been done on mouse
urine [36, 37], mouse kidneys [32] and mouse cell culture
media [33]. Of the twelve identified plasma metabolites
which we found to be associated with eGFR, pseudo uri-
dine and uric acid have long been known to be present in
uremic serum [38] and these compounds have more re-
cently been shown to be markers of high risk or progres-
sion to ESRD in type 2 diabetes [39]. Higher baseline
serum uric acid in ADPKD patients has also been retro-
spectively associated with a high risk of ESRD [40] and
uric acid is increased in the urine of a juvenile cystic
mouse model [37]. One study found an association be-
tween increased serum uric acid and decreased creatinine
clearance rate in ADPKD, without any evidence of in-
creased uric acid production [41], a second study found
ADPKD patients had a higher incidence of hyperuricemia
Table 4 Plasma lipids significantly (p < 0.05) associated with baseline eGFR. Effect size represents the magnitude and direction (+/−)
of association between a given lipid and eGFR, estimated by linear regression, while controlling for the selected HALT covariates,
age, sex, genotype, site of sample collection, and BMI
Lipid Effect Size (SD) p-value FDR q-value
Acylcarnitine(10:1) [M + H]+ −0.0424 (0.013) 0.0010 0.0737
Triglyceride(53:3) [M + K]+ −0.0516 (0.017) 0.0033 0.1024
Acylcarnitine(14:2) [M + H]+ −0.0303 (0.011) 0.0057 0.1024
Acylcarnitine(12:1) [M + H]+ −0.0350 (0.013) 0.0059 0.1024
Acylcarnitine(8:0) [M + H]+ −0.0291 (0.011) 0.0071 0.1024
Triglyceride(54:5) A [M + K]+ −0.0470 (0.020) 0.0199 0.2364
Phosphatidylcholine(28:0) [M + H]+ 0.0275 (0.012) 0.0229 0.2364
Phosphatidylcholine(38:7) [M + H]+ 0.0578 (0.028) 0.0397 0.2959
Triglyceride(59:3) [M + NH4]+ −0.0320 (0.015) 0.0399 0.2959
Diglyceride(32:0) [M + K]+ 0.0506 (0.025) 0.0409 0.2959
Phosphatidylcholine(30:0) [M + H]+ 0.0307 (0.015) 0.0477 0.3137
Table 5 Plasma lipids significantly (p < 0.05) associated with baseline ht-TKV. Effect size represents the magnitude and direction
(+/−) of association between a given lipid and ht-TKV, estimated by linear regression, while controlling for the selected HALT
covariates, age, sex, genotype, site of sample collection, and BMI
Lipid Effect Size (SD) p-value FDR q-value
Triglyceride(51:3) [M + K]+ 0.1626 (0.038) < 0.0001 0.0031
Triglyceride(53:3) [M + K]+ 0.1827 (0.055) 0.0010 0.0492
Sphingomyelin(d43:1) [M + H]+ 0.1560 (0.070) 0.0276 0.5728
Triglyceride d5(17:0/17:1/17:0) iSTD [M + Na]+ 0.1038 (0.049) 0.0337 0.5728
Triglyceride(54:5) A [M + K]+ 0.1350 (0.064) 0.0352 0.5728
Triglyceride(52:3) [M + K]+ 0.1719 (0.082) 0.0360 0.5728
bold Q-values indicate signficance, <0.05
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than patients with CKD or normal renal function despite
all groups having normal rates of uric acid excretion [29]
and a third study found ADPKD patients with normal
renal function had elevated serum uric acid [42]. Neither
study found evidence of increased uric acid synthesis. The
CRISP study found that higher baseline serum uric acid
was not associated with declines in eGFR or increases in
ht-TKV in ADPKD patients over a 6-year period [10] so
the mechanism behind a higher incidence of hyperuricemia
in ADPKD remains unresolved. We are currently undergo-
ing analyses to determine if any of these 12 metabolites at
baseline in ADPKD are predictive of faster disease progres-
sion. In addition, urine metabolites are being evaluated for
a future study, as it is clear that there is high biomarker po-
tential in this biofluid [8, 37, 43, 44].
Several metabolites, including indole-3-lactate and likely
the unknown compound 191801, are microbial metabo-
lites, the former being the end-product of tryptophan me-
tabolism produced by gut microbes [45], and the latter is
found in wine, microalgae, fungi and yeast, as well as in hu-
man urine and plasma and is therefore likely a microbial
metabolite (please see https://binvestigate.fiehnlab.ucdavi-
s.edu/#/bin/191801 for further analytical information on
the metabolite 191801 as well as in what species it has
been observed). Indole-3-lactate and indole-3-acetate are
both present in the urine of a juvenile cystic mouse model
[37]. Meanwhile creatinine, which is a component of the
CKD-EPI eGFR equation, was found to be significantly as-
sociated with eGFR levels, which serves as a supportive
positive internal control for the analysis presented here.
We found significant associations between two large
chain length triglycerides and baseline values of ht-TKV
in ADPKD patients. This kind of association between spe-
cific triglycerides and a marker of progression risk has not
been previously described in early ADPKD patients with
relatively intact kidney function. Lipid dysregulation is
associated with ADPKD in mouse models, including im-
paired fatty acid oxidation in the kidney [32] and upregu-
lation of apolipoprotein-related genes in PKD-1 null
kidneys [31]. Fatty acid metabolism was found to be al-
tered in ADPKD patients both with normal renal function
(HALT A) and decreased renal function (HALT B) [46]. A
(a)
(b)
Fig. 3 Altered associations between a given metabolite/lipid and outcome, eGFR, by effect modifiers sex and genotype. A different color
represents a different sex and genotype. The length and direction of bar indicate a degree and direction (negative or positive) of association with
that metabolite/lipid respectively (see Additional file 2: Tables S1 and S2 for details)
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comparison between ADPKD with normal kidney func-
tion and healthy patients found only 3 components of
metabolic syndrome were increased in ADPKD patients,
namely hypertension, fasting glycemia and abdominal
obesity [47]. A different study of young ADPKD patients
with normal renal function found increased insulin resist-
ance, inflammation and low density lipoprotein (LDL) in
ADPKD [42]. A study in Southern India found ADPKD
patients of a wide variety of ages had moderately increased
plasma triglycerides, LDL and very low density lipoprotein
(VLDL), and a ~ 50% reduction in high density lipoprotein
(HDL) compared to healthy controls [48]. The Consor-
tium for Radiologic Imaging Studies of Polycystic Kidney
Disease (CRISP) cohort 6-year study found baseline serum
HDL-cholesterol levels had a protective effect against in-
creased kidney growth and faster declines in GFR [10].
Hypertriglyceridemia is not a feature of ADPKD in
contrast to CKD (reviewed in [49]), which is also charac-
terized by changes in acylcarnitine levels (reviewed in
[50]). We are currently undergoing analyses to determine
if the plasma triglyceride concentrations at baseline in
ADPKD are predictive of faster disease progression.
We also evaluated the metabolites when accounting
for sex and genotype as possible effect modifiers in their
association with outcome. We found evidence that
metabolite-outcome associations might be altered by sex
or by genotype. However, none of the metabolites were
found to be significant at FDR q < 0.05 when controlling
for multiple testing so neither sex nor PKD genotype are
likely a differentiating factor in the association of all or
most metabolites with those outcomes, but nonetheless
further investigation is warranted.
In summary, we have shown the presence of metabolites
and lipids which highly correlate with eGFR and ht-TKV in
(a)
(b)
Fig. 4 Altered associations between a given metabolite/lipid and outcome, ht-TKV, by effect modifiers sex and genotype. A different color
represents a different sex and genotype. The length and direction of bar indicate a degree and direction (negative or positive) of association with
that metabolite/lipid respectively (see Additional file 2: Tables S1 and S2 for details)
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ADPKD patients with normal kidney function. These me-
tabolites and lipids can be useful for uncovering metabolic
derangements, as well as reprogramming, which appear to
occur early in disease. With further evaluation we may find
additional predictors of early kidney dysfunction that are
potentially less costly than measuring ht-TKV, which is
currently the only measurement known to predict the rate
of disease progression. Perhaps these metabolites will allow
for prognostication and stratification of patients into slow
and rapid progressors to ESRD in ADPKD.
Conclusions
This study identifies metabolic derangements in early
ADPKD which may be prognostic for ADPKD disease
progression. Such data will be useful for future studies
designed to predict outcome of disease based on such
early metabolic changes and will likely lead to new
therapeutic paradigms for a disease with quite limited
therapeutic options.
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